7 completed. 7 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 7 |
| Phase 1 | 2 | Completed 2 |
Follow Drug Eruptions: new trials by email Literature Review of Drug Eruptions trials Research Report on Drug Eruptions
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Topical Diclofenac on Clinical Outcome in Breast Cancer Patients Treated With Capecitabine (CARBAMIDE®), (VOLTAREN®) Emulgel 1% - Hand and Foot Syndrome | Phase 2 | Completed | German University in Cairo | 86 | 2022-12-08 | 2024-01-03 |
| Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis Riboflavin - Chemical Injuries, Unspecified Complication of Corneal Transplant | Phase 1 / Phase 2 | Completed | Joseph B. Ciolino, MD | 1 | 2012-03-01 | 2019-10-21 |
| Effectiveness Allopurinol Topical Agent Prevention Capecitabine-induced Hand-foot Syndrome Allopurinol, Placebo - Hand-foot Syndrome | Phase 2 | Completed | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 60 | 2011-07-01 | 2014-05-23 |
| Safety and Efficacy Placebo Controlled Study of ATH008 Cream in PPES Patients Secondary to Capecitabine ATH008 - Palmar-Plantar Erythrodysesthesia Syndrome | Phase 2 | Completed | Advancell - Advanced In Vitro Cell Technologies, S.A. | 122 | 2011-02-01 | 2014-01-30 |
| Study of 0.1% Uracil Topical Cream (UTC) for the Prevention of Hand-Foot Syndrome Cream, 0.1% Uracil Cream - Palmar-Plantar Erythrodysesthesia, Breast Cancer | Phase 1 / Phase 2 | Completed | Nanometics (d.b.a. PHD Biosciences) | 18 | 2010-04-01 | 2019-10-08 |
| DOXIL for Consolidation Therapy in Ovarian Cancer. liposomal doxorubicin - Ovarian Neoplasm | Phase 2 | Completed | Southeastern Gynecologic Oncology | 45 | 2005-10-01 | 2011-10-12 |
| Topical Antiperspirant for Hand-Foot Syndrome antiperspirant - Palmar-plantar Erythrodysesthesia | Phase 2 | Completed | University of Wisconsin, Madison | 14 | 2005-05-01 | 2015-10-05 |
Hand-Foot Syndrome (6) · Breast Neoplasms (2) · Arthritis, Rheumatoid (1) · Autoimmune Diseases (1) · Hyaline Fibromatosis Syndrome (1) · Lupus Erythematosus, Systemic (1) · Ovarian Neoplasms (1) · Pemphigoid, Benign Mucous Membrane (1) · Stevens-Johnson Syndrome (1)
Chemically-Induced Disorders (7) · Dermatitis (7) · Drug Hypersensitivity (7) · Drug-Related Side Effects and Adverse Reactions (7) · Skin Diseases (7) · Skin and Connective Tissue Diseases (7) · Neoplasms (3) · Neoplasms by Site (3) · Breast Diseases (2) · Adnexal Diseases (1) · Arthritis (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Conjunctival Diseases (1) · Connective Tissue Diseases (1)
Allopurinol (1) · Antiperspirants (1) · Diclofenac (1) · Riboflavin (1) · Solutions (1) · Urea (1) · liposomal doxorubicin (1)
Advancell - Advanced In Vitro Cell Technologies, S.A. (1) · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (1) · German University in Cairo (1) · Joseph B. Ciolino, MD (1) · Nanometics (d.b.a. PHD Biosciences) (1) · Southeastern Gynecologic Oncology (1) · University of Wisconsin, Madison (1)
United States (4) · Spain (2) · Belgium (1) · Egypt (1) · Germany (1) · Italy (1)
Dr. A. Awada (1) · James Cantrell, MD (1) · Jeffrey F Hines, MD, FACOG (1) · Joseph Ciolino, MD (1) · Paul R Hutson, PharmD (1)